Sep 14 2011
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer. The trial, chaired by Prof. Günter Emons, Chairman, Department of Obstetrics & Gynaecology, Georg-August University Göttingen, Germany, was conducted by the German AGO Study Group and centers in Bulgaria. The presentation was made by Pauline Wimberger, M.D., Assistant Director, Gynaecology and Obstetrics Clinic, University of Duisburg-Essen, Germany, during a poster session at the 17th International Meeting of the European Society of Gynaecological Oncology (ESGO) currently being held in Milan, Italy.
"The safety and efficacy of AEZS-108 in our study on advanced endometrial cancer was very encouraging", commented Dr. Wimberger. "Although used as a single agent treatment only, AEZS-108 achieved good response rates and disease stabilization. Personally, I was impressed to see three responses in the five patients treated at my institution, including one long-lasting complete response."
Juergen Engel, Ph.D., President and CEO of Aeterna Zentaris added, "We would first like to thank Dr. Wimberger and all those involved in this trial for their dedicated work which is now being presented to the international gynaecological community. We are very excited about these final results achieved with AEZS-108 alone, which compare favourably with those usually seen with more aggressive and less well tolerated combination regimens for endometrial cancer. On this basis, we have requested Parallel Scientific Advice from both the FDA and the EMA for the further pivotal development of AEZS 108 in this indication in the upcoming months."
Air pollution linked to head and neck cancer risk